Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel PD-1+ TOX-indifferent Synthetic Effector State
J. Corria-Osorio, S. J. Carmona, E. Stefanidis, M. J. Andreatta, T. Muller, Y. Ortiz, B. Seijo, W. Castro, C. Jimenez-Luna, L. Scarpellino, C. Ronet, A. Spill, E. Lanitis, S. A. Luther, P. Romero, , G. Coukos
This study shows that orthogonal gene engineering of CD8+ T cells with IL-2 variant, PD1-decoy, and IL-33 enables tumor control through a novel PD-1+ TOX-indifferent synthetic effector state.
bioRxiv · Feb 18, 2022 · PreprintImmunology